No Data
Does Sansure Biotech (SHSE:688289) Have A Healthy Balance Sheet?
Sansure Biotech's Q3 Profit Plunges 81%
Shengxiang Biology: Shengxiang Biotechnology Co., Ltd. Report for the Third Quarter of 2024
Shengxiang Biotechnology Co., Ltd. Report for the Third Quarter of 2024
sansure biotech inc. (688289.SH): The net income in the first three quarters was 0.195 billion yuan, a year-on-year decrease of 34.8%.
On October 23, Sansure Biotech Inc. (688289.SH) released its third-quarter report, with revenue of 1.03 billion yuan, a year-on-year increase of 63.24%; net income of 0.195 billion yuan, a year-on-year decrease of 34.8%; non-GAAP net income of 0.151 billion yuan, a year-on-year increase of 637.21%; basic earnings per share of 0.34 yuan.
Sansure Biotech Inc. (688289.SH): The product sub-influenza virus type 1, 2, and 3 nucleic acid detection kit has obtained the registration certificate for medical instruments.
On October 17, Gelonhui | Sansure Biotech Inc. (688289.SH) announced that the company's product influenza virus subtypes 1, 2, 3 nucleic acid detection kit (Fluorescent PCR method) recently received the "Medical Device Registration Certificate" issued by the National Medical Products Administration. This product is used for qualitative detection of subtypes 1, 2, and 3 of influenza virus nucleic acid in throat swab samples.
No Data
No Data